{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["53(10)"],"submitter":["Zheng H"],"pubmed_abstract":["<h4>Background</h4>Atherosclerosis is the leading cause of cardiovascular disease worldwide, including in China. Primary prevention, through lipid-lowering, could avert development of atherosclerosis. Carotid intima-media thickness (CIMT) is a well-validated measure of atherosclerosis used in intervention studies as the primary outcome and alternative end point for cardiovascular disease events.<h4>Methods</h4>This randomized, double-blind, placebo-controlled, multicenter, parallel-group study assessed the effects of rosuvastatin 20 mg/d compared with placebo on progression of CIMT over 104 weeks in Chinese people with subclinical atherosclerosis. The primary end point was the annualized rate of change in mean of the maximum CIMT measurements taken 7× over the study period from each of 12 "],"journal":["Stroke"],"pagination":["3004-3013"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9508961"],"repository":["biostudies-literature"],"pubmed_title":["Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study."],"pmcid":["PMC9508961"],"pubmed_authors":["Dong Y","Fu W","Fu Y","Zhang N","Meng X","Bots ML","Zheng H","Nie Z","Chen Y","Wang Y","Yuan Z","Li H","Zheng Z","Zhao B","Wei D","METEOR-China Investigators","Xu E","Hu B","Li X","Li Z","Peng D","Karlson BW","Hu H","Zhang X","Cao S","Cai Y","Fu L","Hong W","Yue W","Ma G"],"additional_accession":[]},"is_claimable":false,"name":"Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.","description":"<h4>Background</h4>Atherosclerosis is the leading cause of cardiovascular disease worldwide, including in China. Primary prevention, through lipid-lowering, could avert development of atherosclerosis. Carotid intima-media thickness (CIMT) is a well-validated measure of atherosclerosis used in intervention studies as the primary outcome and alternative end point for cardiovascular disease events.<h4>Methods</h4>This randomized, double-blind, placebo-controlled, multicenter, parallel-group study assessed the effects of rosuvastatin 20 mg/d compared with placebo on progression of CIMT over 104 weeks in Chinese people with subclinical atherosclerosis. The primary end point was the annualized rate of change in mean of the maximum CIMT measurements taken 7× over the study period from each of 12 ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-06-18T07:06:02.147Z","creation":"2025-04-19T22:47:54.576Z"},"accession":"S-EPMC9508961","cross_references":{"pubmed":["36017704"],"doi":["10.1161/STROKEAHA.120.031877"]}}